Achieve, Disc, and Revolution Among Recipients of First FDA National Priority Vouchers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 17 2025
0mins
Should l Buy REGN?
Source: SeekingAlpha
FDA Priority Review Vouchers: Achieve Life Sciences, Disc Medicine, and Revolution Medicines are among the first recipients of the FDA's National Priority Review vouchers, aimed at expediting the review process for important medicines, reducing timelines from 10-12 months to 1-2 months.
Market Reactions: Following the announcement, Achieve Life Sciences and Disc Medicine saw significant premarket gains of approximately 25% and 20%, respectively, while Revolution Medicines increased by about 9% due to its pancreatic cancer therapy receiving a voucher.
Other Recipients: Other pharmaceutical companies, including Regeneron, Sanofi, and EMD Serono, also received priority review vouchers, with EMD Serono's fertility treatment Pergoveris highlighted by President Trump for its potential to lower costs in the market.
Program Goals: The FDA's pilot program is designed to encourage the development of drugs that address significant national priorities, such as unmet medical needs and domestic drug manufacturing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy REGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on REGN
Wall Street analysts forecast REGN stock price to rise
22 Analyst Rating
16 Buy
6 Hold
0 Sell
Moderate Buy
Current: 749.290
Low
637.00
Averages
808.50
High
1057
Current: 749.290
Low
637.00
Averages
808.50
High
1057
About REGN
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Piper Sandler Initiates Regeneron with Overweight Rating, Anticipates Growth
- Sales Growth Outlook: Piper Sandler has initiated coverage on Regeneron Pharmaceuticals (REGN) with an overweight rating, projecting continued growth in Dupixent (dupilumab) sales, which are expected to surge approximately 50% from 2025 to 2030, reaching around $20 billion by the end of that period, indicating strong market potential.
- Price Target Set: The analyst has set a price target of $875, based on the March 30 close, implying about a 17% upside, reflecting optimistic market expectations for Regeneron's future performance.
- Competitive Strategy: Regeneron has effectively countered competition from standard-dose Eylea (aflibercept) by launching Eylea HD, which now accounts for 47% of sales in the U.S. market, demonstrating the company's adaptability and competitiveness in the market.
- Underappreciated Pipeline Potential: The analyst emphasized that Regeneron's pipeline assets are undervalued, particularly the Factor XI antibody program, which is modeled to peak at risk-adjusted sales of $2.7 billion, significantly higher than the consensus estimate of $1.1 billion, indicating its innovative potential in anticoagulation therapy.
See More
Market Trends Analysis for Regeneron Pharmaceuticals
- Market Insights: In the latest Motley Fool video, experts analyze market dynamics for Regeneron Pharmaceuticals, providing deep insights into future investment opportunities that help investors grasp industry trends.
- Investment Opportunity Assessment: The market trends discussed in the video may present new investment opportunities for investors, particularly in the biopharmaceutical sector, where Regeneron stands out as a leading player worth monitoring.
- Stock Price Reference: The stock price data used in the video is from February 11, 2026, reflecting market sentiment towards Regeneron at that time, allowing investors to evaluate its future potential.
- Expert Opinion Sharing: Through in-depth analysis by experts, viewers can better understand Regeneron's position in the biopharmaceutical industry and its future prospects, enhancing confidence in investment decisions.
See More
Investment Insights on Regeneron Pharmaceuticals
- Market Trend Analysis: In the latest Motley Fool video, analysts discuss market trends surrounding Regeneron Pharmaceuticals, noting that while the company did not make the list of the top 10 recommended stocks, it still garners investor interest.
- Return Comparison: The average return of Stock Advisor stands at 884%, significantly outperforming the S&P 500's 179%, indicating that investors should be cautious in stock selection, with Regeneron's performance needing further observation.
- AI and Investment Opportunities: The video highlights the potential for AI to create the world's first trillionaire, emphasizing the importance of technology in future investments, with Regeneron, as a biotech firm, potentially benefiting from this trend.
- Investor Community: Motley Fool encourages investors to join their community to share investment experiences and strategies, suggesting that although Regeneron is not on the recommended list, its market potential remains noteworthy.
See More
FDA Accelerates Biosimilar Drug Development and Approves New Treatments
- Accelerated Biosimilar Development: On March 9, 2026, the FDA recommended streamlining unnecessary clinical pharmacokinetic studies when scientifically justified, aiming to expedite biosimilar drug development and improve medicine affordability, thereby enhancing market competitiveness.
- Alternative to Animal Testing: The FDA released draft guidance on March 18, 2026, to assist drug developers in validating new approach methodologies as alternatives to animal testing, reflecting its commitment to scientific rigor and humane practices, which could reshape drug development standards.
- New Therapy Approval: On March 10, 2026, the FDA approved Wellcovorin as the first treatment for cerebral folate deficiency, a rare neurological condition, marking a significant advancement in neuroscience and potentially offering new hope for patients.
- Gene Therapy Innovation: The FDA approved Rocket Pharma's Kresladi on March 26, 2026, as the first gene therapy for Severe Leukocyte Adhesion Deficiency Type I, showcasing the potential of gene therapy in treating rare diseases and possibly driving stock price increases for related biotech companies.
See More
AstraZeneca's Lung Disease Drug Meets Trial Targets
- Successful Trials: AstraZeneca's experimental drug tozorakimab met its targets in two late-stage clinical trials, significantly reducing flare-ups in chronic obstructive pulmonary disease (COPD) patients, leading to a nearly 5% increase in the company's stock price.
- Massive Market Potential: With approximately 400 million people diagnosed with COPD globally, AstraZeneca forecasts peak annual sales for tozorakimab between $3 billion and $5 billion, far exceeding the pre-trial market estimate of $1 billion, highlighting its substantial commercial potential.
- Scientific Breakthrough: The trial results represent the first successful confirmatory Phase III trials for an IL-33 biologic, with AstraZeneca's executive vice president noting the significant scientific implications for COPD treatment strategies.
- Future Development Plans: AstraZeneca aims to launch over 20 new drugs in the next five years and has set a target of achieving $80 billion in annual sales by 2030, demonstrating its ambitious vision in the biopharmaceutical sector.
See More
Regeneron Faces Challenges but Shows Potential for Recovery
- Patent Expiration Impact: Regeneron's Eylea drug losing patent exclusivity has led to revenue pressures, yet the company's long-term returns remain solid, indicating market confidence in its future prospects.
- Sales Growth of Key Products: Dupixent, Regeneron's flagship product, is expected to continue growing through the early 2030s, particularly in treating conditions like wet age-related macular degeneration, which will help boost company revenues.
- Advancements in Drug Development: Regeneron is working on a gene therapy for genetic hearing loss, which could launch in the coming years if clinical trial data is favorable, further enriching its product portfolio and driving sales growth.
- Weight Loss Market Strategy: The company is developing two new products in the weight loss sector, with one candidate showing promising results in a phase 3 study in China, potentially positioning Regeneron as a notable player in the rapidly expanding weight loss market.
See More
Piper Sandler Initiates Regeneron with Overweight Rating, Anticipates Growth
- Sales Growth Outlook: Piper Sandler has initiated coverage on Regeneron Pharmaceuticals (REGN) with an overweight rating, projecting continued growth in Dupixent (dupilumab) sales, which are expected to surge approximately 50% from 2025 to 2030, reaching around $20 billion by the end of that period, indicating strong market potential.
- Price Target Set: The analyst has set a price target of $875, based on the March 30 close, implying about a 17% upside, reflecting optimistic market expectations for Regeneron's future performance.
- Competitive Strategy: Regeneron has effectively countered competition from standard-dose Eylea (aflibercept) by launching Eylea HD, which now accounts for 47% of sales in the U.S. market, demonstrating the company's adaptability and competitiveness in the market.
- Underappreciated Pipeline Potential: The analyst emphasized that Regeneron's pipeline assets are undervalued, particularly the Factor XI antibody program, which is modeled to peak at risk-adjusted sales of $2.7 billion, significantly higher than the consensus estimate of $1.1 billion, indicating its innovative potential in anticoagulation therapy.
See More
Market Trends Analysis for Regeneron Pharmaceuticals
- Market Insights: In the latest Motley Fool video, experts analyze market dynamics for Regeneron Pharmaceuticals, providing deep insights into future investment opportunities that help investors grasp industry trends.
- Investment Opportunity Assessment: The market trends discussed in the video may present new investment opportunities for investors, particularly in the biopharmaceutical sector, where Regeneron stands out as a leading player worth monitoring.
- Stock Price Reference: The stock price data used in the video is from February 11, 2026, reflecting market sentiment towards Regeneron at that time, allowing investors to evaluate its future potential.
- Expert Opinion Sharing: Through in-depth analysis by experts, viewers can better understand Regeneron's position in the biopharmaceutical industry and its future prospects, enhancing confidence in investment decisions.
See More
Investment Insights on Regeneron Pharmaceuticals
- Market Trend Analysis: In the latest Motley Fool video, analysts discuss market trends surrounding Regeneron Pharmaceuticals, noting that while the company did not make the list of the top 10 recommended stocks, it still garners investor interest.
- Return Comparison: The average return of Stock Advisor stands at 884%, significantly outperforming the S&P 500's 179%, indicating that investors should be cautious in stock selection, with Regeneron's performance needing further observation.
- AI and Investment Opportunities: The video highlights the potential for AI to create the world's first trillionaire, emphasizing the importance of technology in future investments, with Regeneron, as a biotech firm, potentially benefiting from this trend.
- Investor Community: Motley Fool encourages investors to join their community to share investment experiences and strategies, suggesting that although Regeneron is not on the recommended list, its market potential remains noteworthy.
See More
FDA Accelerates Biosimilar Drug Development and Approves New Treatments
- Accelerated Biosimilar Development: On March 9, 2026, the FDA recommended streamlining unnecessary clinical pharmacokinetic studies when scientifically justified, aiming to expedite biosimilar drug development and improve medicine affordability, thereby enhancing market competitiveness.
- Alternative to Animal Testing: The FDA released draft guidance on March 18, 2026, to assist drug developers in validating new approach methodologies as alternatives to animal testing, reflecting its commitment to scientific rigor and humane practices, which could reshape drug development standards.
- New Therapy Approval: On March 10, 2026, the FDA approved Wellcovorin as the first treatment for cerebral folate deficiency, a rare neurological condition, marking a significant advancement in neuroscience and potentially offering new hope for patients.
- Gene Therapy Innovation: The FDA approved Rocket Pharma's Kresladi on March 26, 2026, as the first gene therapy for Severe Leukocyte Adhesion Deficiency Type I, showcasing the potential of gene therapy in treating rare diseases and possibly driving stock price increases for related biotech companies.
See More
AstraZeneca's Lung Disease Drug Meets Trial Targets
- Successful Trials: AstraZeneca's experimental drug tozorakimab met its targets in two late-stage clinical trials, significantly reducing flare-ups in chronic obstructive pulmonary disease (COPD) patients, leading to a nearly 5% increase in the company's stock price.
- Massive Market Potential: With approximately 400 million people diagnosed with COPD globally, AstraZeneca forecasts peak annual sales for tozorakimab between $3 billion and $5 billion, far exceeding the pre-trial market estimate of $1 billion, highlighting its substantial commercial potential.
- Scientific Breakthrough: The trial results represent the first successful confirmatory Phase III trials for an IL-33 biologic, with AstraZeneca's executive vice president noting the significant scientific implications for COPD treatment strategies.
- Future Development Plans: AstraZeneca aims to launch over 20 new drugs in the next five years and has set a target of achieving $80 billion in annual sales by 2030, demonstrating its ambitious vision in the biopharmaceutical sector.
See More
Regeneron Faces Challenges but Shows Potential for Recovery
- Patent Expiration Impact: Regeneron's Eylea drug losing patent exclusivity has led to revenue pressures, yet the company's long-term returns remain solid, indicating market confidence in its future prospects.
- Sales Growth of Key Products: Dupixent, Regeneron's flagship product, is expected to continue growing through the early 2030s, particularly in treating conditions like wet age-related macular degeneration, which will help boost company revenues.
- Advancements in Drug Development: Regeneron is working on a gene therapy for genetic hearing loss, which could launch in the coming years if clinical trial data is favorable, further enriching its product portfolio and driving sales growth.
- Weight Loss Market Strategy: The company is developing two new products in the weight loss sector, with one candidate showing promising results in a phase 3 study in China, potentially positioning Regeneron as a notable player in the rapidly expanding weight loss market.
See More
